Alzheimer's and Oxidative Stress
Alzheimer's disease affects over 50 million people worldwide and remains without a cure. A growing body of evidence points to oxidative stress and neuroinflammation as key drivers of disease progression — and NRF2 sits at the center of the body's defense against both.
NRF2 Dysfunction in Alzheimer's
Research has consistently shown that NRF2 signaling is impaired in Alzheimer's patients:
- Reduced nuclear NRF2 levels in hippocampal neurons (the brain's memory center)
- Increased KEAP1 expression in AD brain tissue
- Decreased expression of NRF2 target genes (HO-1, NQO1) in affected regions
- Epigenetic silencing of NRF2 through promoter methylation
How NRF2 Activation Could Help
A remarkable 2025 study published in the International Journal of Molecular Sciences revealed that NRF2 negatively regulates BACE1 — the enzyme responsible for producing amyloid-beta, the toxic protein that forms plaques in Alzheimer's brains. This finding connects NRF2 directly to the amyloid cascade, the central pathway in AD pathology.
Additional neuroprotective mechanisms include:
- Anti-inflammatory: NRF2 inhibits NF-κB signaling, reducing microglial activation
- Mitochondrial protection: NRF2 maintains mitochondrial membrane potential and biogenesis
- Proteostasis: NRF2 enhances proteasome activity and autophagy for protein clearance
- Synaptic protection: NRF2 influences synaptic plasticity and neurogenesis
FDA-Approved NRF2 Activators in Neurodegeneration
Two NRF2 activators are already FDA-approved: Dimethyl fumarate (Tecfidera, approved for MS) and Omaveloxolone (Skyclarys, approved 2023 for Friedreich's ataxia). Both demonstrate that pharmacological NRF2 activation is clinically feasible for neurological conditions. Preclinical studies show DMF also has benefits in AD models.
Novel Approaches: WDR23 and BACH1
Cutting-edge research has identified WDR23, a KEAP1-independent NRF2 regulator specifically in the hippocampus, opening possibilities for brain-specific NRF2 enhancement. Additionally, BACH1 inhibitors like HPPE offer a non-electrophilic approach to NRF2 activation with fewer off-target effects.